Lymphocyte activation and serine-esterase induction following recombinant interleukin-2 infusion for lymphomas and acute leukaemias.

Abstract

In this study we investigated the pattern of T lymphocyte changes in 16 adult patients with acute myeloid leukaemia (8), non-Hodgkin's lymphoma (4) and Hodgkin's disease (4) treated with continuous infusion of recombinant interleukin-2 (rIL-2). Effects indicative of lymphocyte activation occurred even prior to any rIL-2 therapy in these patients, being most prominent in patients with active diseases. Following each course of cytokine therapy, there were further changes in these parameters. Significant rebound lymphocytoses occurred with a concomitant increase in the cytotoxic functions and induction of the cytotoxicity-linked cytoplasmic serine esterase. Hence, both the natural killer and lectin-dependent cellular cytotoxicity activities were up-regulated. There were also increases in the serum sIL-2 receptor, sCD4 and sCD8 levels. More CD3+ lymphocytes, especially cells bearing CD4, were also recruited to the pool of potential effector cells, as demonstrated by the greater proportion of cells expressing the cytoplasmic serine esterase.

• Authors: S H Lim, C Worman, A Jewell, C Tsakona, F J Giles, A Goldstone
• Journal: Cancer immunology, immunotherapy : CII (Cancer Immunol Immunother) Vol. 33 Issue 2 Pg. 133-7 ( 1991) ISSN: 0340-7004 [Print] Germany
• PMID: 2036661 (Publication Type: Journal Article)

Chemical References

• Antigens, CD
• Interleukin-2
• Receptors, Interleukin-2
• Recombinant Proteins
• Esterases
• serine esterase

Topics

• Adult
• Antigens, CD (analysis)
• Cytotoxicity, Immunologic
• Enzyme Induction
• Esterases (biosynthesis)
• Hodgkin Disease (immunology, therapy)
• Humans
• Interleukin-2 (pharmacology, therapeutic use)
• Leukemia, Myeloid, Acute (immunology, therapy)
• Lymphocyte Activation
• Lymphoma, Non-Hodgkin (immunology, therapy)
• Receptors, Interleukin-2 (analysis)
• Recombinant Proteins (pharmacology, therapeutic use)